CRVO:NASDAQ, CervoMed Inc.
CRVO stock overview
CervoMed Inc. (CRVO:NASDAQ) closed at $2.27 on October 23, 2026,
up 1.34% on the day.
The stock trades 77.3% below its 52-week high of $10.00
and 6.6% above its 52-week low of $2.13.
Over the past year, it lost 68.4%.
CervoMed Inc. is part of the Health Care sector.
Key figures
- Price
- $2.27
- Day change
- +1.34%
- Volume
- 43,786
- Average volume
- 279,178
- Market cap
- 34M+
- 52-week range
- $2.13 – $10.00
- 50-day average
- $2.63
- 200-day average
- $3.68
Price action over the past year
In 252 trading sessions since October 22, 2025, CRVO closed higher on 101 days (40%).
Its best day was June 16, 2026 (+82.26%) and its worst was June 10, 2026 (-22.15%).
The stock moved 10% or more in a single session 13 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
CRVO news
-
Oct 12, 2026:
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
-
Sep 28, 2026:
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
-
Sep 22, 2026:
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
-
Sep 10, 2026:
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
-
Sep 8, 2026:
CervoMed to Participate in September Investor Conferences
-
Aug 6, 2026:
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
-
Aug 5, 2026:
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
-
Aug 5, 2026:
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
About CervoMed Inc.
Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer.
Similar stocks
Find more stocks like CRVO with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.